Immunicum AB (publ) Receives Regenerative Medicine Advanced Therapy Designation from FDA for Ilixadencel in Kidney Cancer

What we doOur approachPipelineTechnologyPatient Stories
About usManagementBoardClinical Advisory BoardCareers
Newsroom
InvestorsPress releases

Back
Immunicum AB (publ) Receives Regenerative Medicine Advanced Therapy Designation from FDA  for Ilixadencel in Kidney Cancer
 8:00:00 AM

Keep reading
Immunicum AB (publ) Announces Peter Suenaert to Resume Role as Chief Medical OfficerRead